ASAHI INTECC (7747) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Revenue and profit both increased, with a substantial rise in earnings, primarily driven by the expansion of the Medical Business and improved profitability in the Device Business. Revenue was ¥1,083.7B (+18.0% YoY), Operating Income was ¥374.1B (+45.5%), Ordinary Income was ¥372.1B (+45.4%), and Net Income was ¥267.2B (+203.2%). The Operating Margin improved by 6.5pt to 34.5%, from 28.0% in the same period of the previous year, and profit growth exceeding the rate of revenue growth indicates positive operating leverage. The substantial increase in Net Income was aided by extraordinary gains, including a ¥15.3B gain on the sale of investment securities; therefore, the sustainability of earnings power should be assessed based on Operating Income.

Factors Affecting Performance

【Revenue】Revenue was ¥1,083.7B (+18.0% YoY). The core Medical Business generated external revenue of ¥947.7B (+14.6%), accounting for 87.5% of consolidated revenue, while the Device Business continued its high growth with revenue of ¥262.5B (+32.1%). Both businesses recorded revenue growth, indicating that growth is broad-based rather than concentrated in a specific business.

【Profit and Loss】Operating Income was ¥374.1B (+45.5%), and Ordinary Income was ¥372.1B (+45.4%), indicating that strong operating performance was maintained through to the ordinary income level. Segment profit margins improved in both businesses, with the Medical Business at 38.1% (33.1% in the previous year) and the Device Business at 27.7% (19.4% in the previous year); however, the magnitude of improvement was greater in the Device Business. Net Income surged to ¥267.2B (+203.2%), largely due to the base effect from extraordinary gains, including a ¥15.3B gain on the sale of investment securities, resulting in a net gain of ¥5.8B, as well as the reversal of the ¥93.0B impairment loss recorded in the same period of the previous year. In conclusion, both revenue and profit increased.

Segment Analysis

The Medical Business is the core business, with external revenue of ¥947.7B (+14.6% YoY) and segment profit of ¥361.3B (+31.8%), accounting for 83.2% of total reported segment profit of ¥434.1B. The Device Business generated external revenue of ¥262.5B (+32.1%) and segment profit of ¥72.7B (+88.6%). Although smaller in scale, it exceeded the consolidated company-wide results in both profit growth and the degree of profit margin improvement, serving as an additional growth driver. Revenue and profit growth in both businesses confirm a company-wide trend of increasing revenue and profit.

Key Financial Indicators

【Profitability】The Operating Margin was 34.5%, improving by 6.5pt from 28.0% in the same period of the previous year, reflecting a high-value-added business structure indicated by the 70.9% Gross Margin. The Net Profit Margin improved substantially to 24.6% from 9.6% in the same period of the previous year, although the contribution of extraordinary gains should be noted.【Cash Quality】Cash and deposits were ¥598.0B, accounting for 29.3% of total assets and ensuring a substantial liquidity position supported by operating activities.【Investment Efficiency】ROE was 16.0%, with the high Net Profit Margin serving as the primary driver, while the ratio of revenue to total assets remains at a level with room for improvement.【Financial Soundness】The Equity Ratio was extremely high at 82.0%. Interest-bearing debt, consisting of ¥23.7B in short-term debt and ¥48.6B in long-term debt, was minimal relative to total assets, indicating an earnings structure that does not rely on financial leverage.

Cash Flow Analysis

Although detailed disclosure of the statement of cash flows is not available, trends in the balance sheet indicate that Cash and deposits were ¥598.0B, an increase of ¥56.0B from ¥542.0B in the previous year. Inventories of ¥958.1B consisted of ¥95.8B in finished products, ¥74.7B in raw materials, and ¥96.9B in work-in-process, with raw materials increasing year on year, suggesting an expansion in production activities accompanying revenue growth. Current liabilities remained limited to ¥227.3B against current assets of ¥1,145.4B, maintaining a substantial level of working capital. Non-current liabilities were ¥138.4B, including ¥48.6B in long-term borrowings; however, their ratio to total assets was small, and the funding structure was centered on shareholders’ equity.

Earnings Quality

The profit growth rates through the ordinary income level—Operating Income at +45.5% and Ordinary Income at +45.4%—were nearly identical, indicating that the impact of non-operating income and expenses was limited. Non-operating expenses included a ¥3.7B foreign exchange loss and ¥1.0B in interest expenses, exceeding non-operating income such as ¥0.5B in dividend income; consequently, Ordinary Income was slightly below Operating Income. Extraordinary income and expenses included a ¥15.3B gain on the sale of investment securities and a ¥1.6B valuation loss on investment securities, among other items, resulting in a net gain of ¥5.8B and contributing to Net Income of ¥267.2B. Comprehensive Income was ¥328.7B, exceeding Net Income of ¥267.2B by ¥61.5B. The primary factor was a ¥65.5B increase in foreign currency translation adjustments, with the yen-denominated valuation of overseas assets creating a divergence between Comprehensive Income and Net Income.

Earnings Forecast and Guidance

The full-year earnings forecasts are revenue of ¥1,411.4B (+17.6% YoY), Operating Income of ¥422.2B (+40.4%), and Ordinary Income of ¥426.9B (+44.4%). The Q3 cumulative progress rates were 76.8% for revenue, 88.6% for Operating Income, and 87.2% for Ordinary Income, exceeding the standard progress rate of 75%. In particular, cumulative Operating Income growth of 45.5% exceeds the full-year forecast growth rate of 40.4%, indicating an upside trend. No revisions were made to either the earnings forecasts or the dividend forecast this time.

Shareholder Returns

The full-year dividend forecast is ¥46.10 per share, implying a Payout Ratio of 40.1% against the full-year forecast EPS of ¥114.88. Q3 cumulative EPS was ¥100.13, representing progress of 87.2% toward the full-year forecast, and the earnings growth trend is supporting the funding source for dividends. The financial foundation, comprising an Equity Ratio of 82.0% and Cash and deposits of ¥598.0B, supports the continuation of dividends. No revision was made to the dividend forecast this time.

Risk Factors

1. Business concentration risk: The Medical Business accounts for 87.5% of consolidated external revenue and 83.2% of reported segment profit, creating a structure in which changes in sales volume or the regulatory environment for this business could materially affect consolidated results.

2. Foreign exchange risk: A ¥3.7B foreign exchange loss was recorded under non-operating expenses, and foreign exchange movements associated with foreign-currency transactions and overseas expansion are a factor affecting fluctuations in Ordinary Income. While foreign currency translation adjustments of +¥65.5B contributed positively to Comprehensive Income, they are subject to change depending on the period.

3. Valuation risk associated with investment securities: Investment securities totaled ¥185.3B, accounting for 9.1% of total assets. Although a ¥15.3B gain on sale boosted Net Income during the period, a ¥1.6B valuation loss was also recorded. Future non-recurring income and expenses may fluctuate due to changes in market prices.

Industry Benchmark (Reference; Company Analysis)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the Operating Margin and Net Profit Margin substantially exceeded the industry median, placing the company among the high-profitability group within the industry.

Growth and Capital Efficiency

The Revenue Growth Rate also substantially exceeded the industry median, placing the company among the industry leaders in both profitability and growth.

※Source: Company aggregation

Key Takeaways from the Earnings

1. The Operating Margin of 34.5% and Net Profit Margin of 24.6% substantially exceeded the industry median. The high profitability of the Medical Business and the improvement in the Device Business profit margin (+8.3pt YoY) are driving consolidated profitability.

2. The Operating Income progress rate against the full-year forecast was 88.6%, exceeding the standard progress rate and confirming an upside trend. However, the Operating Margin required in Q4, calculated backward from the progress rate, is below the 34.5% recorded during the cumulative first three quarters; therefore, expense recognition at the fiscal year-end will determine the degree to which the forecast is achieved.

3. The +203.2% YoY increase in Net Income includes the ¥15.3B gain on the sale of investment securities and the reversal of the previous year’s impairment loss. Accordingly, when assessing the sustainability of the earnings base, it is appropriate to focus on trends in Operating Income and segment profit margins.

Theoretical Share Price (Reference Value)

Sensitivity: ¥814–¥862 at ±1% for the Cost of Equity, and ¥832–¥845 at ±0.1 for ω.

Notes:

• Because the progress of Net Income against the full-year forecast is 87%, exceeding the standard level of 75%, forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of schedule tend to exceed forecasts; in businesses with strong seasonality, the adjustment may be excessive).
• Net assets as of the quarter-end have been used (there is a timing gap relative to the full-year forecast).
• Because Net Assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information aggregated by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was strong, with accelerating operating profitability and a balance sheet that remains exceptionally conservative. Revenue rose 18.0% YoY to ¥108.37bn. Operating income increased 45.5% to ¥37.41bn, materially outpacing sales growth. The operating margin expanded 652bp YoY to 34.5% from 28.0%. Gross margin increased 306bp to 70.9%, indicating a favorable mix and/or manufacturing-cost absorption. SG&A increased only 7.4% YoY to ¥39.37bn, well below revenue growth, reducing the SG&A-to-sales ratio by 346bp to 36.3%. Ordinary income similarly rose 45.4% to ¥37.21bn. Net income attributable to owners increased 204.2% to ¥26.66bn, although the headline growth rate is flattered by the prior-year ¥9.30bn impairment loss. Current-period pre-tax profit also included a net ¥0.58bn extraordinary gain, comprising a ¥1.53bn gain on sales of investment securities and ¥0.95bn of extraordinary losses. The securities-sale gain represented 4.0% of pre-tax profit, so it modestly lifted reported profit but does not alter the fundamentally strong operating result. The Medical business remained the core business, generating ¥36.13bn of segment profit, or 83.2% of aggregate segment profit before corporate-cost adjustments. The Device business delivered the fastest growth, with external sales increasing 49.6% YoY to ¥13.60bn and segment profit rising 88.6% to ¥7.27bn. Annualized ROE was 21.3%, supported predominantly by a 24.6% net margin rather than balance-sheet leverage. Liquidity is abundant, with ¥59.80bn of cash, a 503.9% current ratio and only ¥7.23bn of interest-bearing debt. The principal operational caution is working-capital intensity: production inventories comprising raw materials, work in process and finished goods imply 232 inventory days and a 251-day cash conversion cycle. Full-year guidance was unchanged despite Q3 operating-profit progress of 88.6%, above the normal 75% seasonal benchmark, leaving scope for results to exceed plan if the current margin profile is maintained.

Profitability Analysis

Annualized DuPont ROE is 21.3%, decomposed into a 24.6% net profit margin, 0.709x annualized asset turnover and 1.22x financial leverage. The dominant driver is profitability rather than leverage: the 34.5% operating margin is well above the 15% excellence benchmark, while leverage remains low. Gross margin rose from 67.8% to 70.9%, a 306bp expansion, and SG&A discipline added further operating leverage as SG&A grew 7.4% against 18.0% revenue growth. Consequently, operating margin improved from 28.0% to 34.5%, or 652bp. Medical segment profit increased 31.8% to ¥36.13bn on 14.6% external-sales growth to ¥94.77bn; its segment margin expanded to 38.1% from 33.1%. Device segment profit grew 88.6% to ¥7.27bn; segment revenue including intersegment sales rose 32.1% to ¥26.25bn, lifting segment margin to 27.7% from 19.4%. Medical is the core business by profit contribution, while Device is becoming an important incremental-margin contributor. The 0.705 tax burden is normal and the 1.010 interest burden reflects negligible financing drag together with the net positive effect of non-operating and extraordinary items. Interest coverage of 377.9x confirms that borrowing costs are immaterial to earnings. Profitability appears operationally robust, but the 24.6% net margin includes the ¥0.58bn net extraordinary gain and should be assessed primarily through the 34.5% operating margin.

Growth Assessment

Revenue growth of 18.0% was broad-based across the two reported businesses. Medical external sales increased ¥12.05bn to ¥94.77bn, while Device external sales increased ¥4.51bn to ¥13.60bn. The faster Device expansion indicates growing scale in the manufacturing platform, although Medical remains the dominant earnings source. Aggregate segment profit increased 38.8% to ¥43.41bn, exceeding aggregate segment-sales growth of 17.9%, demonstrating strong incremental margins. Corporate-cost adjustment widened only ¥0.44bn to ¥5.99bn, allowing most segment-level profit growth to flow through to consolidated operating income. Full-year guidance calls for ¥141.14bn of revenue, ¥42.22bn of operating income and ¥30.56bn of net income attributable to owners. Q3 cumulative progress is 76.8% for revenue, 88.6% for operating income, 87.2% for ordinary income and 87.2% for net income. Operating-income progress is 13.6 percentage points above the standard 75% Q3 benchmark, while ordinary-income and net-income progress are each 12.2 points above it. The unchanged forecast therefore appears conservative relative to year-to-date profitability, although Q4 execution, foreign-exchange effects and working-capital requirements remain relevant. Current-period foreign-exchange losses were ¥0.37bn, equal to only 1.0% of operating income, limiting the present earnings impact.

Financial Health

Financial health is very strong. The current ratio is 503.9% and the quick ratio is 461.7%, supported by current assets of ¥114.54bn against current liabilities of ¥22.73bn. Working capital totals ¥91.81bn, providing substantial capacity to absorb operating volatility and near-term obligations. Cash and deposits of ¥59.80bn are 25.26 times short-term loans of ¥2.37bn. Interest-bearing debt is limited to ¥7.23bn, equivalent to a 0.22x debt-to-equity ratio and 4.1% debt-to-capital ratio. Long-term loans declined ¥1.77bn, or 26.7% YoY, to ¥4.86bn, while short-term loans were broadly stable at ¥2.37bn. The short-term debt ratio is 32.7%, but the maturity profile presents no material mismatch because cash alone substantially exceeds short-term borrowings and current assets are more than five times current liabilities. Total liabilities declined to ¥36.57bn from ¥41.83bn, while total equity increased 10.4% to ¥167.16bn. Capital adequacy improved to 81.6% from 77.9%. Accounts payable increased 27.3% to ¥3.38bn, and electronically recorded obligations increased to ¥0.73bn; this partly supports the working-capital funding cycle. Goodwill declined 73.6% to only ¥0.29bn, eliminating meaningful M&A-related impairment exposure. Treasury stock moved from negative ¥4.45bn to negative ¥0.18bn, consistent with a substantial reduction or cancellation of treasury shares; this change, alongside the ¥2.91bn decline in capital surplus, should be monitored as a capital-structure event rather than an operating driver. Asset retirement obligations of ¥0.20bn equal approximately 0.5% of liabilities, indicating limited disclosed environmental-remediation balance-sheet exposure.

Notable B/S Changes

Treasury stock: improved by ¥4.44bn (+99.6%) to negative ¥0.18bn from negative ¥4.45bn — substantial reduction or cancellation of treasury shares, accompanied by a ¥2.91bn decline in capital surplus; monitor capital-allocation treatment. Goodwill: decreased by ¥0.81bn (-73.6%) to ¥0.29bn — goodwill is now immaterial at 0.0% of equity and assets, materially reducing future impairment sensitivity. Accounts payable: increased by ¥0.73bn (+27.3%) to ¥3.38bn — partially extends supplier financing during revenue growth, but remains modest relative to the broader production inventory balance. Long-term loans: decreased by ¥1.77bn (-26.7%) to ¥4.86bn — further strengthens the already conservative capital structure and reduces financing-risk exposure.

Cash Flow Quality

Operating-cash-flow and free-cash-flow conversion cannot be quantified from the reported figures. Balance-sheet working-capital indicators nevertheless identify a material cash-absorption risk. Finished goods reported on the balance sheet are ¥9.58bn, equivalent to approximately 83 annualized inventory days based on annualized Q3 cost of sales; this exceeds the 60-day manufacturing benchmark and directly addresses the 83-day high-inventory alert. Including disclosed raw materials of ¥7.47bn, work in process of ¥9.69bn and finished goods of ¥9.58bn produces production inventory of ¥26.98bn, equivalent to approximately 232 annualized days; this addresses the separate 232-day alert. The difference between the two inventory measures reflects the distinction between balance-sheet inventory presentation and the broader manufacturing inventory breakdown. Receivables, including electronically recorded monetary claims, total ¥21.25bn and imply roughly 54 annualized collection days. Trade payables and electronically recorded obligations total ¥4.11bn and imply roughly 36 annualized payment days. The resulting broader production-cycle cash conversion cycle is approximately 251 days, directly addressing the long-CCC alert above the 120-day warning threshold. This extended cycle increases exposure to demand forecasting errors, production bottlenecks and inventory obsolescence, particularly as the company expands manufacturing output. The 49.6% increase in Device external sales provides some context for inventory investment, but sustained inventory growth should be matched by sales conversion and stable gross margins.

Dividend Sustainability

The full-year dividend forecast is ¥46.10 per share, with no revision announced at Q3. Based on forecast EPS of ¥114.88, the indicated dividend payout ratio is 40.1%. This is below the 60% sustainability benchmark and leaves a meaningful earnings retention buffer. The balance sheet provides further support, with ¥59.80bn of cash and low interest-bearing debt of ¥7.23bn. Annualized ROE of 21.3% also suggests retained earnings are being deployed at an attractive reported return. Dividend sustainability will ultimately depend on cash conversion through the extended manufacturing working-capital cycle and ongoing production investment requirements.

Risk Assessment

Business risks include High priority — Inventory and production-cycle risk: broader manufacturing inventories of ¥26.98bn imply 232 annualized inventory days, while the 251-day cash conversion cycle is substantially above the 120-day warning benchmark. A slowdown in medical-device demand, product-mix change or production disruption could increase obsolescence and tie up cash., Medium priority — Medical-business concentration: Medical generated 83.2% of aggregate segment profit before corporate-cost adjustments. Its performance is therefore central to consolidated earnings, despite faster Device growth., Medium priority — Medical-device manufacturing risk: quality control, regulatory compliance, product approval timing, supplier continuity and recall risk can affect production volumes, margins and customer relationships., Medium priority — Foreign-exchange risk: current FX losses were limited at ¥0.37bn, but overseas sales and manufacturing activities can expose earnings and equity to currency fluctuations; foreign-currency translation adjustment in equity was ¥20.79bn..

Financial risks include Low priority — Securities-related earnings volatility: the ¥1.53bn gain on sale of investment securities increased pre-tax profit, while valuation-related losses remain possible. Investment securities of ¥18.53bn represent 9.1% of total assets., Low priority — Working-capital funding sensitivity: liquidity is currently ample, but a prolonged 251-day production cash cycle would reduce cash flexibility if inventory conversion deteriorates., Low priority — Defined-benefit obligation: net defined-benefit liability was ¥3.36bn, modest relative to ¥167.16bn of total equity..

Key concerns include The HIGH_INVENTORY_DAYS alert based on 83 days indicates finished-goods inventory is above the 60-day manufacturing benchmark., The HIGH_INVENTORY_DAYS alert based on 232 days indicates that raw materials, WIP and finished goods together create a much longer production-cycle exposure; WIP of ¥9.69bn is a significant component and may signal throughput or lead-time sensitivity., The LONG_CCC alert of 251 days is the principal financial-quality concern because receivables and inventory are converted into cash slowly relative to manufacturing benchmarks., Headline net-income growth of 204.2% is not fully recurring because the prior-year comparison included a ¥9.30bn impairment loss and current profit includes a net ¥0.58bn extraordinary gain., The unchanged full-year forecast despite above-benchmark profit progress creates execution expectations for Q4, even though year-to-date performance is favorable..

Investment Implications

Key takeaways include Operating momentum is strong: revenue grew 18.0%, operating income grew 45.5%, and operating margin expanded 652bp to 34.5%., Medical remains the profit engine, while Device is the faster-growing business and delivered substantial margin expansion., Annualized ROE of 21.3% is high quality in capital-structure terms because it is driven by margins and asset utilization rather than leverage., The company has substantial financial flexibility, with a 503.9% current ratio, ¥59.80bn of cash and only ¥7.23bn of interest-bearing debt., Inventory intensity and the 251-day cash conversion cycle are the key factors that could temper cash realization of reported earnings., Full-year operating-income progress of 88.6% versus a 75% Q3 benchmark is favorable relative to unchanged guidance..

Metrics to watch include Medical and Device segment sales growth and segment-profit margins, Finished-goods inventory days and total production inventory days, Work-in-process balance and cash conversion cycle, Operating cash flow relative to net income and capital expenditure, Q4 operating margin versus the 34.5% Q3 cumulative level, Foreign-exchange gains or losses and valuation changes in investment securities, Execution against full-year revenue guidance of ¥141.14bn and operating-income guidance of ¥42.22bn.

Regarding relative positioning, The company screens as a high-margin, high-return medical-device manufacturer with a notably stronger balance sheet than a debt-funded growth profile would imply. Its principal relative constraint is not solvency but manufacturing working-capital efficiency, where the broader inventory cycle is long versus standard manufacturing benchmarks.